氟达拉滨
医学
养生
T细胞受体
内科学
肿瘤科
环磷酰胺
软组织肉瘤
过继性细胞移植
临床试验
胃肠病学
T细胞
免疫学
外科
软组织
化疗
免疫系统
作者
Qiuzhong Pan,Desheng Weng,Jiayong Liu,Zhaosheng Han,Yusheng Ou,Bu-Shu Xu,Ruiqing Peng,Yi Que,Xizhi Wen,Jing Yang,Zhong Shi,Lun Zeng,Aiyuan Chen,Haiping Gong,Yanmei Lin,Jiewen Chen,Ke Ma,Johnson Y. N. Lau,Yi Li,Zhengfu Fan
标识
DOI:10.1016/j.xcrm.2023.101133
摘要
New York esophageal squamous cell carcinoma-1 (NY-ESO-1)-specific T cell receptor (TCR) T cell therapy is effective in tumors with NY-ESO-1 expression, but a safe and effective TCR-T cell therapeutic protocol remains to be improved. Here, we report a phase 1 investigational new drug clinical trial with TCR affinity-enhanced specific T cell therapy (TAEST16001) for targeting NY-ESO-1. Enrolled patients receive TAEST16001 cell infusion after dose-reduced lymphodepletion with cyclophosphamide (15 mg/kg/day × 3 days) combined with fludarabine (20 mg/m2/day × 3 days), and the TCR-T cells are maintained with low doses of interleukin-2 injection post-adoptive transfer. Analysis of 12 patients treated with the regimen demonstrates no treatment-related serious adverse events. The overall response rate is 41.7%. The median progression-free survival is 7.2 months, and the median duration of response is 13.1 months. The protocol of TAEST16001 cells delivers a safe and highly effective treatment for patients with advanced soft tissue sarcoma (ClinicalTrials.gov: NCT04318964).
科研通智能强力驱动
Strongly Powered by AbleSci AI